| name | endo-mets-assessment-body-fat-distribution-obesity |
| description | Advises assessment of metabolic syndrome components and body fat distribution to accurately determine cardiovascular disease risk in individuals with obesity. Trigger phrases include "Patient with obesity needing CVD risk assessment", "Evaluating metabolic syndrome in obese patient", and "Assessing body fat distribution for cardiovascular risk". |
Assessment of metabolic syndrome components and body fat distribution in obesity
STEP 1 — Gather Information
Collect BMI, waist circumference (or waist/hip ratio), blood pressure, fasting lipid panel (triglycerides, HDL-C), fasting glucose or HbA1c, current medications, and ethnicity-specific waist cutoffs.
STEP 2 — Rule In / Rule Out
Determine if the patient meets ≥3 of the following MetS criteria: TG ≥150 mg/dL or on TG-lowering medication; HDL-C <50 mg/dL (women) or <40 mg/dL (men); waist circumference ≥102 cm (men) or ≥88 cm (women) (adjust to ≥90 cm for East/South Asian men and ≥80 cm for women); systolic BP ≥130 mm Hg or diastolic ≥85 mm Hg or on antihypertensive medication; prediabetes by fasting glucose 100–125 mg/dL, 2‑h OGTT 140–199 mg/dL, or HbA1c 5.7–6.4%. If ≥3 criteria are present, rule in MetS; otherwise rule out MetS.
STEP 3 — Classify or Stratify
If MetS is present, stratify CVD risk by counting MetS components and noting waist circumference; calculate 10‑year atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations (requires age, sex, race, total cholesterol, HDL‑C, systolic BP, hypertension treatment, diabetes status, smoking). Classify risk as low (<5%), borderline/intermediate (5–19.9%), or high (≥20%).
STEP 4 — Decide
If 10‑year ASCVD risk ≥20% or ≥7.5% with ≥1 risk‑enhancing factor (including MetS), initiate moderate‑ to high‑intensity statin after risk discussion; if borderline/intermediate risk (5–19.9%) consider coronary artery calcium (CAC) scoring to reclassify risk; if low risk (<5%) reinforce lifestyle measures (diet, exercise, weight loss) and reassess lipids after 5% weight loss.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on BMI alone; waist circumference may be misleading in BMI >35 kg/m²; use ethnic‑specific cutoffs; avoid mislabeling prediabetes; remember that lifestyle‑induced lipid changes do not reduce CVD events; reassess lipid profile after weight loss or bariatric surgery; do not omit hyperglycemia assessment.
Concrete Clinical Example
A 48‑year‑old Hispanic man with BMI 36, waist 100 cm, TG 170 mg/dL, HDL‑C 38 mg/dL, BP 132/84 mm Hg, fasting glucose 108 mg/dL meets 4 MetS criteria; Pooled Cohort Equations give 10‑year ASCVD risk 14%; decision: start moderate‑intensity statin plus lifestyle counseling.
Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674
TODO: consider adding scripts/calc.py for the endo-mets-assessment-body-fat-distribution-obesity calculator
